A series of sulfonyl-N-hydroxyguanidine derivatives was designed and synthesized for cytotoxic evaluation as potential anticancer agents on the basis of the lead compound LY-181984. Replacement of the ureido moiety of the lead compound with hydroxyguanidine provided a stable cytotoxic agent. The conformation of sulfonyl-N-hydroxyguanidine derivatives, such as N-(4-chlorophenyl)-N'-[(benzo[2,1,3]th
以
铅化合物LY-181984为基础,设计合成了一系列磺酰基-N-
羟基胍衍
生物,作为潜在的抗癌药进行细胞毒性评价。用
羟基胍代替前导化合物的
脲基部分提供了稳定的细胞毒剂。磺酰基-N-
羟基胍衍
生物的构象,例如N-(4-
氯苯基)-N'-[(苯并[2,1,3]
噻二唑-4-基)磺酰基] -N“-
羟基胍(4g),使用HMBC NMR,理论计算和X射线晶体学研究表明,这两个芳环堆叠在一起,并评估了这些衍
生物对5种人类肿瘤
细胞系的体外细胞毒性,包括HepG2,
TSGH 8302,COLO 205,KB和MOLT -4。衍生化合物对人肿瘤
细胞系的细胞毒活性等于或大于先导化合物。N-(4-
氯苯基)-N'-[[3,5-二
氯-4-(4-
硝基苯氧基)苯基]磺酰基]-N“-
羟基胍(4n)和N-(4-
氯苯基)-N'- [[3,5-二
氯-4-(2-
氯-4-
硝基苯氧基)苯基]磺酰基] -N”-
羟基胍(4o)对实体瘤
细胞系表现